This episode of *On The Pen* dives into three major developments shaping obesity care: Fractyl Health’s groundbreaking GLP-1 + GIP gene therapy, Dr. Mehmet Oz’s hints about potential Medicare coverage for GLP-1s, and the federal court ruling on retatrutide that could redefine compounded access. Together, these stories reveal how science, policy, and regulation are colliding to decide the future of obesity treatment.